FR3091351B1 - Biomarqueur de la maladie de fabry - Google Patents

Biomarqueur de la maladie de fabry Download PDF

Info

Publication number
FR3091351B1
FR3091351B1 FR1874250A FR1874250A FR3091351B1 FR 3091351 B1 FR3091351 B1 FR 3091351B1 FR 1874250 A FR1874250 A FR 1874250A FR 1874250 A FR1874250 A FR 1874250A FR 3091351 B1 FR3091351 B1 FR 3091351B1
Authority
FR
France
Prior art keywords
fabry
disease biomarker
subject
biomarker
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1874250A
Other languages
English (en)
Other versions
FR3091351A1 (fr
Inventor
Soumeya Berri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre Hospitalier Universitaire de Rouen
Original Assignee
Centre Hospitalier Universitaire de Rouen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Hospitalier Universitaire de Rouen filed Critical Centre Hospitalier Universitaire de Rouen
Priority to FR1874250A priority Critical patent/FR3091351B1/fr
Publication of FR3091351A1 publication Critical patent/FR3091351A1/fr
Application granted granted Critical
Publication of FR3091351B1 publication Critical patent/FR3091351B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/50—Fibroblast growth factors [FGF]
    • G01N2333/503—Fibroblast growth factors [FGF] basic FGF [bFGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5418—IL-7
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L’invention consiste en une méthode de diagnostic in vitro de la maladie de Fabry chez un sujet, ladite méthode comprenant une étape de mesure de la concentration d’au moins un biomarqueur choisi parmi : Il-7, FGF-2, AC(16 :1)-OH, spermidine et taurine dans un échantillon biologique dudit sujet.
FR1874250A 2018-12-27 2018-12-27 Biomarqueur de la maladie de fabry Active FR3091351B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR1874250A FR3091351B1 (fr) 2018-12-27 2018-12-27 Biomarqueur de la maladie de fabry

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1874250A FR3091351B1 (fr) 2018-12-27 2018-12-27 Biomarqueur de la maladie de fabry

Publications (2)

Publication Number Publication Date
FR3091351A1 FR3091351A1 (fr) 2020-07-03
FR3091351B1 true FR3091351B1 (fr) 2021-05-21

Family

ID=67810636

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1874250A Active FR3091351B1 (fr) 2018-12-27 2018-12-27 Biomarqueur de la maladie de fabry

Country Status (1)

Country Link
FR (1) FR3091351B1 (fr)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4849077A (en) 1984-08-06 1989-07-18 Akademie Der Wissenschaften Der Ddr Process for solid phase-sequencing of nucleic acid fragments
NO986133D0 (no) 1998-12-23 1998-12-23 Preben Lexow FremgangsmÕte for DNA-sekvensering
US20060275782A1 (en) 1999-04-20 2006-12-07 Illumina, Inc. Detection of nucleic acid reactions on bead arrays
WO2003066896A2 (fr) 2002-02-09 2003-08-14 Nanotype Gmbh Procede de detection de mutations
CA2596496A1 (fr) 2005-02-01 2006-08-10 Agencourt Bioscience Corp. Reactifs, methodes et bibliotheques pour sequencage fonde sur des billes
EP1875401B1 (fr) 2005-06-30 2014-03-05 BIOCRATES Life Sciences AG Dispositif d'analyse quantitative de profil de metabolite
US7556922B2 (en) 2006-03-23 2009-07-07 The Board Of Trustees Of The Leland Stanford Junior University Motion resolved molecular sequencing
US20170205427A1 (en) * 2014-07-23 2017-07-20 University Of British Columbia Biomarkers for anderson-fabry disease

Also Published As

Publication number Publication date
FR3091351A1 (fr) 2020-07-03

Similar Documents

Publication Publication Date Title
EP3757226A3 (fr) Dosage de biomarqueurs multiprotéiniques pour la détection et l'issue de lésions cérébrales
WO2019113525A3 (fr) Procédés d'aide au diagnostic et à l'évaluation d'un sujet qui a subi une lésion orthopédique et qui a subi ou peut avoir subi une lésion à la tête, telle qu'une lésion cérébrale traumatique légère (tbi), à l'aide d'une protéine acide fibrillaire gliale (gfap) et/ou d'hydrolase carboxy-terminale d'ubiquitine l1 (uch-l1)
BR112015003715A8 (pt) análise de raman, de infravermelho, ou de raman-infravermelho da estrutura de proteína de plasma de sangue periférico e sua relação para desenvolvimento cognitivo no mal de alzheimer
Yap et al. Real-time imaging of retinal ganglion cell apoptosis
WO2009121031A4 (fr) Procédé d'identification de nouveaux candidats thérapeutiques via l'analyse d'expression génique dans les maladies d'origine vasculaire
BR112012025870A2 (pt) uso de pelo menos uma razão quantitativa de dois diferentes peptídeos beta-amiloides, metodos e kit para determinar a probabilidade de um paciente contrair a doença de alzheimer (ad)
SG171691A1 (en) Biomarkers for diagnosing multiple sclerosis, and methods thereof
MX2020007864A (es) Medicion de sulfuro de hidrogeno durante prueba de respiracion.
JP2018132526A (ja) 大うつ病性障害及び双極性障害のマーカー、検査方法、検査キット、及び治療薬のスクリーニング方法。
CN108884492A (zh) 借助多中心mirna谱的阿尔茨海默病中的特定标记
BR112014018204A8 (pt) Método de diagnóstico de distúrbio de células beta pancreáticas em um indivíduo
FR3091351B1 (fr) Biomarqueur de la maladie de fabry
MX2022000444A (es) Un biomarcador para la enfermedad de alzheimer utilizando muestras de sangre de sujetos con diagnostico clinico de la enfermedad de alzheimer.
ES2570609T3 (es) Método para someter a ensayo la aminoacilasa 1 para el diagnóstico in vitro del cáncer colorrectal
AU2011291450A8 (en) TAM receptors and TAM receptor ligands in detection and modulation of neuropathological disease
RU2016100626A (ru) Способ прогнозирования тяжести течения и исхода заболевания у пациентов с хирургическим сепсисом
EP4368993A3 (fr) Procédés, utilisations et kits de diagnostic de gingivite
BR112023001575A2 (pt) Método in vitro ou ex vivo para diagnóstico ou prognóstico de doença neurodegenerativa e uso de um kit diagnóstico para implementação do mesmo
BR0209681A (pt) Método e kit para o diagnóstico in vivo ou para o monitoramento de uma doença que envolve uma reação inflamatória dentro de um paciente
RU2018105982A (ru) Способ дифференциальной диагностики форм хронического тонзиллита с использованием раман-флюоресцентной спектроскопии
Piskur Tuberculous meningitis combined with pulmonary tuberculosis in children
FR3100452B1 (fr) Méthode de diagnostic de peaux agées
Bunevicius et al. Thyroid hormone and C-reactive protein serum concentrations, disease severity and discharge outcomes of ischemic stroke patients: a dataset
Melada et al. Comorbid depression and ulcerative colitis–is there a connection?
Huang et al. P3-182 EXAMINING THE ASSOCIATION BETWEEN CIRCULATING INSULIN-LIKE GROWTH FACTOR 1 (IGF-1) AND BRAIN ACTIVITY IN OLDER ADULTS

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20200703

FC Decision of inpi director general to approve request for restoration

Effective date: 20210118

RN Application for restoration

Effective date: 20210118

PLFP Fee payment

Year of fee payment: 3

RM Correction of a material error

Effective date: 20210712

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6